Attralus Presents Positive New Data at 2021 American Society of Hematology Annual Meeting
13 déc. 2021 08h00 HE
|
Attralus, Inc
AT-03 potently binds human AL and ATTR fibrils and is capable of binding diverse forms of systemic amyloid deposits in mouse models AT-03 enhances macrophage-mediated phagocytosis of AL amyloid...
Attralus to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference
22 nov. 2021 08h00 HE
|
Attralus, Inc
SOUTH SAN FRANCISCO, Calif., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with...
Attralus to Present New Data at 2021 American Society of Hematology Annual Meeting
04 nov. 2021 09h00 HE
|
Attralus, Inc
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with...
Attralus Closes $116 Million Series B Financing
08 sept. 2021 07h00 HE
|
Attralus, Inc
- Proceeds to advance pipeline of transformational pan-amyloid removal (PAR) therapeutics into the clinic - Financing led by Logos Capital and included other leading public healthcare funds - ...
Attralus Appoints Jake Bauer to Board of Directors
28 juil. 2021 07h00 HE
|
Attralus, Inc
SOUTH SAN FRANCISCO, Calif., July 28, 2021 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with...